Ionis Pharmaceuticals Inc (NASDAQ: IONS) established initial surge of 4.08% at $43.1, as the Stock market unbolted on Wednesday, before settling in for the price of $41.41 at the close. Taking a more long-term approach, IONS posted a 52-week range of $23.95-$50.43.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Nevertheless, stock’s Earnings Per Share (EPS) this year is 12.37%. This publicly-traded company’s shares outstanding now amounts to $159.20 million, simultaneously with a float of $155.53 million. The organization now has a market capitalization sitting at $6.87 billion. At the time of writing, stock’s 50-day Moving Average stood at $40.18, while the 200-day Moving Average is $35.19.
Ionis Pharmaceuticals Inc (IONS) Ownership Facts and Figures
Sometimes it is also beneficial to study the sentiment of large-scale investors towards the stock of the Ionis Pharmaceuticals Inc industry. Ionis Pharmaceuticals Inc’s current insider ownership accounts for 2.42%, in contrast to 104.12% institutional ownership. According to the most recent insider trade that took place on Aug 06 ’25, this organization’s Director sold 5,000 shares at the rate of 41.93, making the entire transaction reach 209,646 in total value, affecting insider ownership by 86,344. Preceding that transaction, on Aug 05 ’25, Company’s EVP, Chief Development Officer sold 10,000 for 42.86, making the whole transaction’s value amount to 428,593. This particular insider is now the holder of 89,492 in total.
Ionis Pharmaceuticals Inc (NASDAQ: IONS) Trading Performance Indicators
Let’s observe the current performance indicators for Ionis Pharmaceuticals Inc (IONS). It’s Quick Ratio in the last reported quarter now stands at 2.86. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 7.27.
In the same vein, IONS’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.85, a figure that is expected to reach -1.20 in the next quarter, and analysts are predicting that it will be -3.16 at the market close of one year from today.
Technical Analysis of Ionis Pharmaceuticals Inc (IONS)
Now, what If we examine the latest scores posted by [Ionis Pharmaceuticals Inc, IONS]. During the last 5-days, its volume was better the volume of 1.76 million it reported in year-ago period. During the previous 9 days, stock’s Stochastic %D was recorded 41.67% While, its Average True Range was 59.19%.
Raw Stochastic average of Ionis Pharmaceuticals Inc (IONS) in the period of the previous 100 days is set at 88.21%, which indicates a major rise in contrast to 54.53% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 1.44 that was higher than 1.32 volatility it exhibited in the past 100-days period.
